Search Results - Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Developing lay summaries and thank you notes in paediatric pragmatic clinical trials by Kanecia O. Zimmerman, Brian Perry, Emily Hanlen‐Rosado, Adora Nsonwu, Morgan D. Lane, Daniel K. Benjamin, Mara Becker, Amy Corneli, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Connect to this object online.

Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population by Elizabeth J. Thompson, Angela Jeong, Victória E. Helfer, Valentina Shakhnovich, Andrea Edginton, Stephen J. Balevic, Laura P. James, David N. Collier, Ravinder Anand, Daniel Gonzalez, the Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee

Connect to this object online.

Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity by Jacqueline G. Gerhart, Fernando O. Carreño, Jennifer L. Ford, Andrea N. Edginton, Eliana M. Perrin, Kevin M. Watt, William J. Muller, Andrew M. Atz, Amira Al‐Uzri, Paula Delmore, Daniel Gonzalez, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Connect to this object online.

Physiologically‐Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants by Jacqueline G. Gerhart, Kevin M. Watt, Andrea Edginton, Kelly C. Wade, Sara N. Salerno, Daniel K. Benjamin Jr, P. Brian Smith, Christoph P. Hornik, Michael Cohen‐Wolkowiez, Shahnaz Duara, Ashley Ross, Karen Shattuck, Dan L. Stewart, Natalie Neu, Daniel Gonzalez, the Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Connect to this object online.